Structure via PubChem · Public domain (PubChem)
mirabegron
Sign in to saveAlso known as Betmiga®, Myrbetriq®, YM-178
Mirabegron, sold under the brand name Myrbetriq among others, is a medication used to treat overactive bladder. Its benefits are similar to antimuscarinic medication such as solifenacin or tolterodine. It is taken by mouth.
In the Vinony graph
Within Vinony's link graph, mirabegron is referenced by 597 other articles, and connects out to urinary tract infection, propranolol and arterial hypertension.
Vinony files it under Astellas Pharma, Beta3-adrenergic agonists and CYP2D6 inhibitors.
Its subject is documented across 22 Wikipedia language editions.
Chemical data
- Formula
- C21H24N4O2S
- Molecular weight
- 396.5 g/mol
- IUPAC name
- 2-(2-amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide
- SMILES
- C1=CC=C(C=C1)[C@H](CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O
- InChIKey
- PBAPPPCECJKMCM-IBGZPJMESA-N
- XLogP
- 2.1
- Polar surface area
- 129 Ų
- H-bond donors
- 4
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2012
- Admin. routes
- oral
- Indications
- heart failure, pain, liver disease, overactive bladder
via ChEMBL · EBI
Research
1,123 papers- Mirabegron: Pediatric First Approval.Paediatric drugs · 2021
- Mirabegron: The most promising adipose tissue beiging agent.Physiological reports · 2021
- Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis.Lower urinary tract symptoms · 2023
- Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2023
- Activation of β3-adrenergic receptor by mirabegron prevents aortic dissection/aneurysm by promoting lymphangiogenesis in perivascular adipose tissue.Cardiovascular research · 2024
via PubMed
Wikidata facts
- Mass
- 396.162
- Has use
- medication
Show 7 more facts
- chemical formula
- C₂₁H₂₄N₄O₂S
- isomeric SMILES
- C1=CC=C(C=C1)[C@H](CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O
- canonical SMILES
- C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O
- World Health Organisation international non-proprietary name
- mirabegron
- defined daily dose
- 50
- Commons category
- Mirabegron
- physically interacts with
- adrenoceptor beta 3
Sources (7)
via Wikidata · CC0
~5 min read
Encyclopedic overview
5 sectionsContents
- Medical uses
- Adverse effects
- Research
- References
- Further reading
{{Drugbox | image = Mirabegron.svg | image_class = skin-invert-image | width = 300 | alt =
| tradename = Myrbetriq, Betanis, Betmiga, others | Drugs.com = | MedlinePlus = a612038 | DailyMedID = Mirabegron | pregnancy_AU = B3 | pregnancy_category = | routes_of_administration = By mouth | ATC_prefix = G04 | ATC_suffix = BD12
Excerpted from Wikipedia’s “mirabegron” article, available under the CC BY-SA 4.0 licence.